Scott Wise

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Sheng-Bin Peng, James R. Henry, Michael D. Kaufman et al. · Cancer Cell · 2015 · 305 citations · Full text

Ly3009120 Leads, Raf Isoforms, Medicine +8

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Bryan D. Smith, Michael D. Kaufman, Wei-Ping Lu et al. · Cancer Cell · 2019 · 270 citations

Pdgfra Variants, Oncogenic Agent, Medicine +9

Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.

Heidi S. Camp, O Li, Scott Wise et al. · Diabetes · 2000 · 223 citations · Full text

Transcriptional Regulation, Signal Transduction, Receptor Bound +15

cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype

Leia M. Smith, Scott Wise, Denver T. Hendricks et al. · Oncogene · 1999 · 213 citations

Breast Oncology, Cjun Overexpression, Medicine +10

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

Wayne W. Chan, Scott Wise, Michael D. Kaufman et al. · Cancer Cell · 2011 · 204 citations · Full text

Switch-control Inhibitor Dcc-2036, Signal Transduction, Signaling Pathway +9